Extrapulmonary neuroendocrine tumors (NETs) most commonly arise in the gastrointestinal tract. Poorly differentiated high-grade NETs, also known as neuroendocrine carcinoma (NECs), are aggressive with an overall poor prognosis. Treatment options are limited, with first-line platinum-based therapy as standard. Due to the advancement of cancer therapeutics, more reasonable and personalized approaches are available. Our Research Topic will focus on systemic treatment strategies, including chemotherapy, targeted therapy, and immunotherapy.
The goal of this Research Topic is to expand our understanding of novel treatment strategies for NECs. Manuscripts of clinical studies addressing the efficacy of adjuvant/neoadjuvant therapy, chemotherapy, targeted therapy, and immunotherapy, as well as the basic or translational studies investigating the mechanisms and experimental therapies for NECs are welcomed.
We welcome manuscripts in the form of Original Research, Clinical Trials, Reviews, Clinical Case Series, and Perspectives.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords:
gastroenteropancreatic, extrapulmonary neuroendocrine carcinoma, NEC, extrapulmonary neuroendocrine tumors, cancer therapy, targeted therapy
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Extrapulmonary neuroendocrine tumors (NETs) most commonly arise in the gastrointestinal tract. Poorly differentiated high-grade NETs, also known as neuroendocrine carcinoma (NECs), are aggressive with an overall poor prognosis. Treatment options are limited, with first-line platinum-based therapy as standard. Due to the advancement of cancer therapeutics, more reasonable and personalized approaches are available. Our Research Topic will focus on systemic treatment strategies, including chemotherapy, targeted therapy, and immunotherapy.
The goal of this Research Topic is to expand our understanding of novel treatment strategies for NECs. Manuscripts of clinical studies addressing the efficacy of adjuvant/neoadjuvant therapy, chemotherapy, targeted therapy, and immunotherapy, as well as the basic or translational studies investigating the mechanisms and experimental therapies for NECs are welcomed.
We welcome manuscripts in the form of Original Research, Clinical Trials, Reviews, Clinical Case Series, and Perspectives.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords:
gastroenteropancreatic, extrapulmonary neuroendocrine carcinoma, NEC, extrapulmonary neuroendocrine tumors, cancer therapy, targeted therapy
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.